Clinical pharmacology of the serotonin receptor agonist, zolmitriptan

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 6, 2007, Pages 899-911

  Peterlin, B Lee ^a   Rapoport, Alan M ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

5 HT1 receptors; Cardiovascular toxicity; Cluster headache; Eletriptan; Frovatriptan; Headache; Hepatic toxicity; Menstrually related migraine; Migraine; Pediatric migraine; Pregnancy registry; Rizariptan; Serotonin; Serotonin receptor; Serotonin receptor agonists; Sumatriptan; Triptans; Zolmitriptan

Indexed keywords

DIHYDROERGOTAMINE; ELETRIPTAN; FLUOXETINE; FROVATRIPTAN; IBUPROFEN; METOCLOPRAMIDE; NARATRIPTAN; PROPRANOLOL; RIZATRIPTAN; SELEGILINE; SEROTONIN 1 AGONIST; SUMATRIPTAN; XYLOMETAZOLINE; ZOLMITRIPTAN;

AREA UNDER THE CURVE; BLOOD PRESSURE; CHEST TIGHTNESS; CLINICAL TRIAL; DIZZINESS; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MILK LEVEL; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELDERLY CARE; FOOD DRUG INTERACTION; HUMAN; KIDNEY DISEASE; LIVER DISEASE; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL MIGRAINE; NAUSEA; NOSE DISEASE; PARESTHESIA; PHARMACODYNAMICS; PHARYNGITIS; PHARYNX DISEASE; PREGNANCY; REVIEW; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION;

CLINICAL TRIALS AS TOPIC; HUMANS; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; OXAZOLIDINONES; PHARMACOLOGY, CLINICAL; SEROTONIN; SEROTONIN 5-HT1 RECEPTOR AGONISTS; TRYPTAMINES;

EID: 37348999890     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.6.899     Document Type: Review

References (75)

1. HAMEL E, SAXENA PR: 5-Hydroxytryptamine involvement in migraines. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (2006):275-281.
2. FERRARI MD, SAXENA PR: 5-HT1 receptors in migraine pathophysiology and treatment. Eur. J. Neurol. (1995) 2:5-21.
3. 1B/1D receptor agonists in migraine: clinical pharmacology and its therapeutic implications. CNS Drugs (1998) 10(4):271-286.
4. HUMPHREY PPA: 5-Hydroxytryptamine and the pathophysiology of migraine. J. Neurol. (1991) 238:S38-S44.
5. RAPOPORT AM, BIGAL ME, TEPPER SJ, SHEFTELL FD: Zolmitriptan (Zomig©). Expert Rev. Neurother. (2004) 4(1):33-41.
6. FRAZER A, HENSLER JULIE G: Serotonin. In: Basic Neurochemistry. Siegel GJ, Agranof BW, Albers RW, Fisher SK, Uhler MD (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (1999):263-292.
7. WAEBER CHRISTIAN: Serotonin and other biogenic amines. In: The Headaches (3rd Edition). Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA (Eds), Lippincott, Williams and Wilkins Publishers, Philadelphia, USA (2006):143-149.
8. 1B receptor knockout mice in stress and anxiety paradigms. Behav. Pharmacol. (2003) 14(5-6):369-383.
9. 1B/1D-receptor agonists in patients with migraine headaches. Clin. Pharmacol. Ther. (2000) 68:418-426.
10. 1B/1D-receptor agonists. Neurology (1997) 48(Suppl. 3):S21-S24.
11. 1B/1D agonist for migraine. Cephalalgia (1997) 17(Suppl. 18):4-14.
12. WURCH T, COLPAERT FC, PAUWELS PJ: Chimeric receptor analysis of the ketanserin binding site in the human 5-hydroxytryptamine1D receptor: importance of the second extrracellular loop and fifth transmembrane domain in antagonist binding. Mol. Pharmacol. (1998) 54:1088-1096.
13. 1-like receptor agonist, GR43175. Cephalalgia (1989) 9(Suppl. 9):23-33.
14. MOSKOWITZ MA, CUTRER FM: Attacking migraine headache from beginning to end. Cephalalgia (1997) 49:1193-1195.
15. GERAUD G, OLESEN J, PFAFFENRATH V et al.: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30-38.
16. DAHLOF C: Clinical applications of new therapeutic deliveries in migraine. Neurology (2003) 61(8)(Suppl. 4):S31-S34.
17. YATES R, NAIRN K, DIXON R, SEABER E: Preliminary studies of the pharrmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J. Clin. Pharmacol. (2002) 42:1237-1243.
18. ZINGMARK PH, YATES R, HEDLUND C, KAGEDAL M: True nasopharyngeal absorption of zolmitriptan following administration of zolmitriptan nasal spray. Eur. J. Neurol. (2003) 10(Suppl. 1):76.
19. MACGREGOR A: Management of migraine in general practice. Prescriber (1998) 19:49-70.
20. GILLOTIN C, BAGNIS C, MARNET JP, PECK RW, DERAY G: No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Int. J. Clin. Pharmacol. Ther. (1997) 35(11):522-526.
21. ROLAN P: Potential drug interactions with the novel antimigraine compound zolmitriptan(Zomig©, 311C90). Cephalalgia (1997) 14(Suppl. 18):21-27.
22. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalagia (2002) 22:633-658.
23. SEABER E, ON N, DIXON RM, GIBBENS M, LEAVENS WJ, LIPTROT J et al.: The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). Br. J. Clin. Pharamacol. (1997) 43:579-587.
24. PALMER KJ, SPENCER CM: Zolmitriptan. CNS Drugs (1997) 7:468-478.
25. SEABER E, ON N, PHILIPS R, CHRUCHUS J, POSNER J, ROLAN P: The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. Br. J. Clin. Pharmacol. (1996) 41:141-147.
26. VERONESE L, GILLOTIN C, MARION-GALLOIS R et al.: Lack of an interaction between oral dihydroergotamine and the novel antimigraine compound zolmitriptan ("Zomig", 311C90) in healthy volunteers. Clin. Drug Invest. (1997) 14:217-220.
27. SYRETT NB, ABU-SHAKRA S, YATES R: Zolmitriptan nasal spray: advances in migraine treatment. Neurology (2003) 61(8)(Suppl. 4):S27-S30.
28. AURORA SK, KORI SH, BARRODALE P, MCDONALD SA, HASELEY D: Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache (2006) 46(1):57-63.
29. UEMURA N, ONISHI T, MITANIYAMA A et al.: Bioequivalence and rapid absorption of zolmitriptan nasal spray compared to oral tablets in healthy Japanese subjects. Clin. Drug Invest. (2005) 25(3):199-208.
30. SMITH DA, CLEARY EW, WATKINS S, HUFFMAN CS, DILZER SC, LASSETER KC: Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind,placebo-controlled study. J. Clin. Pharmacol. (1998) 38(8):685-693.
31. 1D receptor agonist for the acute oral treatment of migraine: a multicentre dose-range finding study. Eur. J. Neurol. (1998) 5:535-543.
32. CHARLESWORTH B, DOWSON AJ: Review of zolmitriptan and its clinical applications in migraine. Expert Opin. Pharmacother. (2002) 3(7):993-1005.
33. PHYSICIANS'DESK REFERENCE. 60th Edition. Thomson, PDR, Montvale, NJ, USA (2006):714-722.
34. LODER E, SILBERSTEIN SD, ABU-SHAKRA S et al.: Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache (2004) 44:120-130.
35. NEWMAN LC, LIPTON RB, LAY CL, SOLOMON S: A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology (1998) 51:307-309.
36. NEWMAN 4 MANNIX LK, LANDY S et al.: Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized double-blind, placebo-controlled study. Headache (2001) 41:248-256.
37. SILBERSTEIN SD, ELKIND AH, SHREIBER C, KEYWOOD C: A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology (2004) 63:261-269.
38. TUCHMAN M, HEE A, EMERIBE U: Oral zolmitriptan 2.5 mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches. Headache (2005) 45:771-772 (Abstract OR13).
39. BRANDES J, MARCUS DA: Migraine management during pregnancy. In: Migraine in Women. Loder E, Marcus DA (Eds), BC Decker, Inc. Publishers, Hamilton, Ontario, USA (2004):112-121.
40. OLESEN C, STEFFENSEN FH, SORENSEN HT, NIELSEN GL, OLSEN J: Pregnancy outcome following prescription for sumatriptan. Headache (2000) 40:20-24.
41. KALLEN B, LYGNER PE: Delivery outcome in women who used drugs fbr migraine during pregnancy with special reference to sumatriptan. Headache (2001) 41:351-356.
42. LINDER SL, DOWSON SJ: Zolmitriptan provides effective migraine relief in adolescents. Int. J. Clin. Pract. (2000) 54:466-469.
43. EVERS S, RAHMANN A, KRAEMER C et al.: Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology (2006) 67:497-499.
44. LEWIS DW, WINNER P, HERSHEY AD et al.: Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics (2007) 120:390-396.
45. 1B/1D receptor agonist zolmitriptan in healthy young and elderly men and women. Clin. Pharmacol. Ther. (1998) 63:342-353.
46. 1D agonist: an overview of efficacy. Cephalalgia (1997) 17(Suppl. 18):28-40.
47. RAPOPORT AM, RAMADAN NM, ADELMAN JU et al.: Optimizing the dose of zolmitriptan (Zomig™, 311C90) for the acute treatment of migraine: a multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology (1997) 49(5):1210-1218.
48. VISSER WH, KLEIN KB, COX RC, JONES D, FERRARI MD: 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology (1996) 46(2):522-526.
49. SOLOMON GD, CADY RK, KLAPPER JA, EARL NL, SAPER JR, RAMADAN NM: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology (1997) 49(5):1219-1225.
50. TUCHMAN M, EDVINSSON L, GERAUD G, KORCZYN A, MAUSKOP A, PFAFFENRATH V: Zolmitriptan provides consistent migraine relief when used in the long-term. Curr. Med. Res. Opin. (1999) 15(4):272-281.
51. GERAUD G, OLESEN J, PEAFFENRATH V et al.: Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia (2000) 20:30-38.
52. GALLAGHER RM: Comparison of zolmitriptan and sumatriptan for the acute treatment of migraine. Cephalalgia (1999) 19:358.
53. BECKER WJ: Zolmitriptan versus sumatriptan comparison trial. Headache (2001) 41:321-323.
54. PASCUAL J, VEGA P, DIENER HC, ALLEN C, VRIJENS F, PATEL K: Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia (2000) 20:455-461.
55. STEINER TJ, DIENER HC, MACGREGOR EA, SCHOENEN J, NUIRHEAD N, SIKES CR: Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia (2003) 23(10):942-952.
56. LODER E, FREITAG FG, ADELMAN J, PEARLMAN S, ABU-SHAKRA S: Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Curr. Med. Res. Opin. (2005) 21(3):381-389.
57. DOWSON AJ, MACGREGOR EA, PURDY RA, BECKER WJ, GREEN J, LEVY SL: Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalagia (2001) 22:101-106.
58. SPIERINGS ELH, RAPOPORT AM, DODICK DW, CHARLESWORTH B: Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs (2004) 18(15):1133-1141.
59. CHARLESWORTH BR: Migraine patients prefer the zolmitriptan orally disintegrating tablet formulation to the rizatriptan wafer tablet formulation: an assessment of taste and ease to use. Headache (2002) 43:332.
60. DOWSON AJ, CHARLESWORTH BR: Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan tablet conventional oral tablet. Int. J. Clin. Pract. (2003) 57(7):573-576.
61. CHARLESWORTH BR, DOWSON AJ, PURDY A, BECKER WJ, BOES-HANSEN S, FARKKILA M: Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomized, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs (2003) 17(9):653-667.
62. DODICK D, BRANDES J, ELKIND A, MATHEW N, RODICHOK L: Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study. CNS Drugs (2005) 19(2):125-136.
63. GAWEL M, ASCHOFF J, MAY A: Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine-results from Phase I of the REALIZE study. Headache (2001) 45:7-16.
64. DIENER HC, EVERS S: Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study. Clin. Drug Investig. (2007) 27(1):59-66.
65. BAHRA A, GAWEL MJ, HARDEBO JE, MILLSON D, BREEN SA, GOADSBY PJ: Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology (2000) 54(9):1832-1839.
66. CITTADINI E, MAY A, STRAUBE A, EVERS S, BUSSONE G, GOADSBY PJ: Effectiveness of intdransal zolmitriptan in acute cluster headache. Arch. Neurol. (2006) 63:1537-1542.
67. RAPOPORT AM, MATHEW NT, SILBERSTEIN SD et al.: Zolmitriptan nasal spray in the acute treatment of cluster headache. Neurology (2007) 69:1-6.
68. DIENER HC, LIMMROTH V: Acute management of migraine: triptans and beyond. Curr. Opin. Neurol. (1999) 12(3):261-267.
69. HALL GC, BROWN MM, MO J, MACRAE KD: Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology (2004) 62(4):563-568.
70. GOBEL H, PETERSEN-BRAUN M, HEINZE A: Which Properties do Patients Expect of New and Improved Drugs in the Treatment of Primary Headache Disorders? In: Headache treatment: trial methodology and new drugs. Olesen J, Tfelt-Hansen P (Eds), Lippincott-Raven Publishers, New York, USA (1997):93-97.
71. HALFORD JC, HARROLD JA, LAWTON CL, BLUNDELL JE: Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets (2005) 6(2):201-213.
72. FILLA SA, MATHES BM, JOHNSON KW et al.: Novel potent 5-HT1F receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-peperidinyl)-1H-pyrrolo[3,2-blpyridin-5- yl]amides. J. Med. Chem. (2003) 46(14):3060-3071.
73. WEISSMAN JT, MA JN, ESSEX A, GAO Y, BURSTEIN ES: G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Gαi regulated pathway. Oncogene (2004) 23:241-249.
74. 35S] GTPγS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur. J. Pharmacol. (1998) 352(8):117-124.
75. SHEPHEARD S, EDVINSSON L, CUMBERBATCH M et al.: Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY334370. Cephalalgia (1999) 19(10):851-858.